Ablynx (ABLYF) Partner Boehringer Ingelheim Corporation Initiates Phase 1 Study With Nanobody to Treat Alzheimer's Disease
10/29/2013 9:31:25 AM
GHENT, Belgium, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer's disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx.
Help employers find you! Check out all the jobs and post your resume.